Switzerland · Delayed Price · Currency is CHF Addex Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw strong preclinical progress in chronic cough and brain injury recovery programs, with robust efficacy and safety data. Financials showed reduced operating loss and extended cash runway, while the Neurosterix spin-out continues to advance key neuropsychiatric assets.
Fiscal Year 2025
-
Significant pipeline progress was made in chronic cough and brain injury recovery programs, with robust preclinical results and new clinical preparations. Financials show reduced cash burn and a cash runway through mid-2026, but further funding is needed for unpartnered programs.
-
Q3 2025 saw steady financials and major R&D progress, including GABAB PAM and Dipraglurant programs advancing toward clinical studies. Cash runway extends to mid-2026, but further funding is needed for unpartnered programs. Chronic cough and post-stroke recovery remain key focus areas.
-
H1 2025 saw major pipeline progress, including IND-enabling studies for GABA-B PAM and M4 PAM programs, regained rights to mGluR2 PAM, and investment in Stalicla. Cash runway extends to mid-2026, but further funding is needed for unpartnered clinical programs.
-
Q1 2025 saw major pipeline progress, including IND-enabling studies for GABA-B PAMs and repositioning of dipraglurant for brain injury recovery. Cash runway extends to mid-2026, but further funding is needed for unpartnered clinical programs.
Fiscal Year 2024
-
Neurosterix spin-out secured CHF 5M and a 20% equity stake, reducing cash burn and enabling focus on core programs. GABAB PAM and dipraglurant programs advanced, but further funding is needed for unpartnered clinical progress. Cash runway extends through mid-2026.
-
GABA-B PAM programs advanced with a compound selected for substance use disorder and promising preclinical results in chronic cough. Q3 2024 saw lower income and expenses, with a strong cash position and continued R&D progress.
-
Neurosterix spin-out secured $63M, strengthening the balance sheet and advancing preclinical assets. GABAB PAM and dipraglurant programs made significant progress, with IND-enabling studies planned for 2025. Revenue and expenses remained stable, with future growth dependent on financing and partnerships.
-
Advanced GABAB PAM and dipraglurant programs, secured CHF 5M and a 20% stake via Neurosterix spin-out, and maintained stable R&D spending. Awaiting full data from Janssen's epilepsy study and preparing for multiple IND-enabling studies in H2 2024.